David M. Weinstock, M.D.  
Assistant Professor of Medicine, Dana Farber Cancer Institute  
The Weinstock laboratory utilizes a range of approaches at the intersection of cancer genetics and DNA repair to address the ontogeny, pathogenesis, and therapeutic targeting of hematologic neoplasms. Our goal is to identify new prognostic markers and therapeutic targets and then translate these into better outcomes for patients with leukemia and lymphoma. We lead an effort at DFCI to develop a large repository of human hematologic malignancy xenografts that can be broadly utilized to test novel therapeutics and interrogate mechanisms of in vivo engraftment and expansion.

Thurs. 1/23/14, 12:30 PM TMEC 448

Steven P. Balk, M.D., Ph.D.  
Professor, Department of Medicine, Harvard Medical School; Staff Physician, Hematology/Oncology, Beth Israel Deaconess Medical Center  
This lab developed methods to analyze advanced metastatic PCa through the use of bone marrow biopsies and showed that one mechanism for disease progression after androgen deprivation therapy was through mutations in the androgen receptor (AR). These mutations occur specifically in patients treated with an AR antagonist, flutamide, and are the result of strong selective pressure exerted by this drug.

Thurs. 2/27/14, 12:30 PM TMEC 333

Daniel Haber, M.D., Ph.D.  
Kurt J. Isselbacher/Peter D. Schwartz Professor of Oncology, Harvard Medical School; Director of the Massachusetts General Hospital Cancer Center  
The Haber Lab focuses on understanding the fundamental genetics of human cancer, from inherited mutations that confer familial predisposition to genetic mutations that are acquired by tumors themselves and may render them susceptible to specific targeted drug therapies. We have identified mutations in the EGFR gene that confer dramatic sensitivity of some lung cancers to drugs that inhibit that pathway, pointing toward the importance of genetic classification of common epithelial cancers in applying novel targeted therapies.

Thurs. 3/27/14, 12:30 PM TMEC 209

Benjamin Ebert, M.D., D.Phil.  
Principal Investigator; Assistant Professor, Harvard Medical School; Hematologist/Oncologist, Brigham and Women's Hospital, Dana-Farber Cancer Institute; Associate member, Broad Institute; Principal faculty member, Harvard Stem Cell Institute  
A major focus of the laboratory is the myelodysplastic syndrome (MDS), a pre-malignant disorder of hematopoietic stem cells that progresses to acute leukemia. In recent work, we identified a gene that plays a central role in the pathophysiology of the 5q- syndrome, a subtype of MDS. Our findings revealed a molecular link between the 5q- syndrome and congenital bone marrow failure syndromes such as Diamond Blackfan Anemia.

Thurs. 4/10/14, 12:30 PM GOLDENSON 122

Bradley Bernstein, M.D., Ph.D.  
Professor of Pathology, Harvard Medical School; Associate Pathologist, Massachusetts General Hospital; Early Career Scientist, Howard Hughes Medical Institute; Senior Associate Member, Broad Institute  
The long-term goal of our research is to achieve a comprehensive understanding of chromatin structure and function in mammalian development and human cancer. We are taking a multi-faceted approach involving stem cell biology, genetics, genomics and computational biology. These studies have led to several discoveries, including the identification of bivalent domains, a novel chromatin structure proposed to keep developmental regulator genes ‘poised’ in pluripotent ES cells.

Tues. 5/13/14, 12:30 PM TMEC 333